Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.

RADNOR, Pa., Aug. 17, 2020 /PRNewswire/ -- UNITED STATES DISTRICT COURT DISTRICT OF ARIZONA Richard Di Donato, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v.

Kessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities Litigation

Johnson & Johnson

McKesson

Mallinckrodt PLC

Bankruptcies reached a new high not seen since 2011, with opioid lawsuits playing a big role.

Biotech Bankruptcies Hit New Record in 2019

John Kapoor, the founder of Insys Therapeutics Inc , on Thursday was sentenced to 66 months in prison for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.

Insys founder Kapoor sentenced to 66 months in prison for opioid scheme

Insys Therapeutics founder John Kapoor was sentenced to 66 months in prison for his role in an opioid fraud scheme by a U.S. district judge in Boston on Thursday.

Insys founder Kapoor sentenced to 66 months in prison: judge

John Kapoor, the founder of Insys Therapeutics Inc, on Thursday could be sentenced to several years in prison and ordered to forfeit up to $113 million for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.

Insys founder faces stiff prison sentence, $100 million-plus in forfeiture

Tilray Brands

All six of these cannabis stocks lost at least a third of their value.

The Worst Pot Stocks in the First Half of 2019

The Nasdaq Stock Market said late Friday it was delisting four stocks that had traded on its exchange.

Nasdaq delists shares of FTD, Insys, others

GW Pharmaceuticals

Eli Lilly

Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.

Opinion: Medical Marijuana Is a Terrible Investment

Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher on approval for the company's First Day motions,
The post Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					4 Top American Penny Pot Stocks (Buy Before June 21)				
			
					
				
					7 Stocks to Buy for the Coming Recession				
			
					
				
					10 Smart Dividend Stocks for the Rest of the Year				
			
					
				
					5 Tech Stocks That Are Far Too Risky Right Now

Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News

Shares of Insys Therapeutics Inc. INSY, -77.67% shot up 83% in premarket trade Wednesday, after the bankrupt opioid maker said it received interim court approvals for its "First Day" motions related to bankruptcy filing on Monday.

Insys Therapeutics' stock jumps after bankruptcy court approves 'First Day' motions

Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

Insys Down on Bankruptcy News Amid Increasing Legal Expenses

The Insys Therapeutics bankruptcy news coming out on Monday about it filing for Chapter 11 has INSY stock tanking hard today.
The post Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News appeared first on InvestorPlace.

Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News

Drugmaker Insys Therapeutics Inc filed for bankruptcy protection on Monday amid mounting expenses driven by a U.S. Justice Department probe into claims it paid doctors bribes to prescribe a powerful opioid medication.

Opioid manufacturer Insys files for bankruptcy after kickback probe

Drugmaker Insys Therapeutics filed for Chapter 11 bankruptcy protection on Monday, about a week after agreeing to pay $225 million to settle a US probe into bribes it paid to doctors for prescribing a powerful opioid medication. The filing in US Bankruptcy Court in the District of Delaware made Insys the first drug manufacturer to.

Insys files for bankruptcy after settling opioid case

Fentanyl-maker Insys Therapeutics Inc. (NASDAQ: INSY) last week agreed to pay a $225 million settlement related to federal criminal and civil charges of illegally marketing its highly addictive Subsys painkiller.

What Insys Therapeutics Gets by Filing for Chapter 11

Insys Therapeutics, Inc. shares are trading sharply lower following news the company initiated a court supervised process to facilitate asset sales via Chapter 11 bankruptcy.

Insys Shares Fall 70% After Filing For Chapter 11 Bankruptcy

Shares of Insys Therapeutics Inc.  plunged 68% toward a record low in premarket trade Monday, after the specialty pharmaceutical company said it filed for bankruptcy.

Insys files for bankruptcy, stock plunges toward record low

Drugmaker Insys Therapeutics Inc filed for Chapter 11 bankruptcy protection on Monday, about a week after agreeing to pay $225 million to settle a U.S. probe into bribes it paid to doctors for prescribing a powerful opioid medication.

Opioid drugmaker Insys Therapeutics files for bankruptcy

Some marijuana stocks are worth a serious look. These aren't.

3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now

Insys Therapeutics Inc (NASDAQ: INSY) Chairman Steven Meyer and board member Pierre Lapalme will resign "upon the execution of the agreements relating to the settlement with the U.S.

Insys Therapeutics Board Members Resign After $225M DOJ Settlement

Aurora Cannabis

Aphria

Cara Therapeutics

Canopy Growth

ETFMG Alternative Harvest ETF

Scotts Miracle-Gro

Should you put your hard-earned money into these stocks? We detail the investment opportunities, the risks, and regulations in the cannabis space.

Investing in Marijuana Stocks: Everything You Need to Know

Though many cannabis investors are seeing green, these pot stocks have gone up in smoke.

3 Marijuana Stocks Hitting All-Time Lows

Opioid drugmaker Insys Therapeutics Inc may soon go bust, the company suggested in the first-quarter earnings report it released Friday after the close.

Insys Plunges 70% After Bankruptcy Warning

The biotech raised the possibility of filing for bankruptcy in its latest earnings report.

Why Insys Therapeutics Stock Is Crashing Today

Shares of Insys Therapeutics Inc. plunged 70% Monday morning, a fall sparked by the biotech's Friday disclosure that mounting legal expenses and declines in the market for fast-acting fentanyl could lead it to file for bankruptcy.

News for Insys Therapeutics Stock (INSY)